1. Elevation of plasma levels of fluorinated pyrimidines by guanosine 5′-monophosphate

   • Masaaki Iigo
   • Ziro Yamaizumi
   • Akio Hoshi

   Original Articles Pages: 1 - 4

2. Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and-resistant murine and human tumour cell lines in vitro

   • Elizabeth M. Gibby
   • Odette Boyse
   • Bridget T. Hill

   Original Articles Pages: 5 - 7

3. Comparative in vitro toxicity of mitoxanatrone and adriamycin in human granulocyte-macrophage progenitor cells

   • H.-G. Mergenthaler
   • P. Brühl
   • E. Heidemann

   Original Articles Pages: 8 - 12

4. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in rabbits

   • J. W. Paxton
   • P. C. Evans
   • R. M. Singh

   Original Articles Pages: 13 - 15

5. Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity

   • R. M. Böhmer
   • K. Hoffmann
   • G. Morstyn

   Original Articles Pages: 16 - 20

6. Reduction of vincristine toxicity by Cronassial

   • K. Hellmann
   • G. E. Hutchinson
   • K. Henry

   Original Articles Pages: 21 - 25

7. A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin

   • Phillip A. Reece
   • Irene Stafford
   • P. Grantley Gill

   Original Articles Pages: 26 - 32

8. Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics

   • Michelle J. Soble
   • Robert T. Dorr
   • Steven Breckenridge

   Original Articles Pages: 33 - 36

9. Phase I clinical trial of ethyl 6-deoxy-3,5-di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809)

   • Patrick J. Creaven
   • Stefan Madajewicz
   • Joan Solomon

   Original Articles Pages: 37 - 40

10. Comparative clinical pharmacology of [¹¹¹In]-labeled murine monoclonal antibodies

    • M. G. Rosenblum
    • J. L. Murray
    • D. Carlo

    Original Articles Pages: 41 - 47

11. High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer

    • Richard Osborne
    • Barrie Evans
    • Eve Wiltshaw

    Original Articles Pages: 48 - 52

12. A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma

    • J. Wagstaff
    • I. Todd
    • D. Crowther

    Original Articles Pages: 53 - 58

13. Drug monitoring of etoposide (VP16-213)

    • Karl-Heinz Pflüger
    • Lothar Schmidt
    • Klaus Havemann

    Original Articles Pages: 59 - 66

14. Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors

    • M. L. Zanette
    • U. Tirelli
    • M. D'Incalci

    Original Articles Pages: 67 - 70

15. Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy

    • Gérard Milano
    • Moise Namer
    • Jean-Noel Bruneton

    Original Articles Pages: 71 - 74

16. Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

    • Robert Milroy
    • Jeffrey Cummings
    • Stephen W. Banham

    Original Articles Pages: 75 - 77

17. Methotrexate (MTX) concentration in tumors following low-dose MTX

    • Naomi J. Winick
    • Barton A. Kamen
    • Dale Coln

    Short Communication Pages: 78 - 80

18. Poly(I) · Poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study

    • Hans-Georg Eichler
    • Robert Mader
    • Hugo Rainer

    Short Communication Pages: 81 - 82

19. Etoposide combination therapy for small cell carcinoma of the lung

    • R. P. Abratt
    • P. A. Willcox
    • R. H. Hewitson

    Short Communication Pages: 83 - 84

20. Metabolism of epidoxorubicin in animals: absence of glucuronidation

    • P. A. Maessen
    • K. B. Mross
    • W. J. F. van der Vijgh

    Short Communication Pages: 85 - 87

21. Meeting announcement

    Announcement Pages: 88 - 88